Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SRPT Sarepta Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: SRPT
Price (delayed)
$36.2
Market cap
$3.56B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.51
Enterprise value
$4.66B
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going
Highlights
The revenue has soared by 59% YoY and by 17% QoQ
SRPT's gross profit is up by 48% year-on-year and by 15% since the previous quarter
The company's equity fell by 25% QoQ but it rose by 19% YoY
Sarepta Therapeutics's quick ratio has decreased by 33% YoY and by 27% from the previous quarter
Sarepta Therapeutics's gross margin has decreased by 7% YoY
Key stats
What are the main financial stats of SRPT
Market
Valuations
Earnings
Shares outstanding
98.28M
Market cap
$3.56B
Enterprise value
$4.66B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.07
Price to sales (P/S)
1.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.09
Revenue
$2.23B
Gross profit
$1.83B
Operating income
-$117.21M
Net income
-$248.39M
EBIT
-$164.19M
EBITDA
-$109.09M
Free cash flow
-$697.55M
Per share
Balance sheet
Liquidity
EPS
-$2.51
EPS diluted
-$2.63
Free cash flow per share
-$7.16
Book value per share
$11.78
Revenue per share
$22.94
TBVPS
$35.59
Total assets
$3.47B
Total liabilities
$2.32B
Debt
$1.34B
Equity
$1.14B
Working capital
$1.83B
Debt to equity
1.18
Current ratio
4.02
Quick ratio
1.95
Net debt/EBITDA
-10.11
Margins
Efficiency
Dividend
EBITDA margin
-4.9%
Gross margin
81.8%
Net margin
-11.1%
Operating margin
-5.2%
Return on assets
-6.9%
Return on equity
-20%
Return on invested capital
-4.3%
Return on capital employed
-5.7%
Return on sales
-7.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SRPT stock price
How has the Sarepta Therapeutics stock price performed over time
Intraday
-0.47%
1 week
-22.57%
1 month
-29.06%
1 year
-72.51%
YTD
-70.23%
QTD
-43.28%
Financial performance
How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$2.23B
Gross profit
$1.83B
Operating income
-$117.21M
Net income
-$248.39M
Gross margin
81.8%
Net margin
-11.1%
SRPT's net margin has dropped by 190% since the previous quarter
SRPT's operating income has dropped by 154% since the previous quarter and by 24% year-on-year
SRPT's operating margin has plunged by 145% from the previous quarter but it is up by 24% YoY
The revenue has soared by 59% YoY and by 17% QoQ
Price vs fundamentals
How does SRPT's price correlate with its fundamentals
Growth
What is Sarepta Therapeutics's growth rate over time
Valuation
What is Sarepta Therapeutics stock price valuation
P/E
N/A
P/B
3.07
P/S
1.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.09
SRPT's P/B is 77% below its 5-year quarterly average of 13.2 and 67% below its last 4 quarters average of 9.2
The company's equity fell by 25% QoQ but it rose by 19% YoY
The P/S is 86% less than the 5-year quarterly average of 11.6 and 76% less than the last 4 quarters average of 6.5
The revenue has soared by 59% YoY and by 17% QoQ
Efficiency
How efficient is Sarepta Therapeutics business performance
Sarepta Therapeutics's ROIC has plunged by 161% from the previous quarter
The ROS has plunged by 154% from the previous quarter
Dividends
What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SRPT.
Financial health
How did Sarepta Therapeutics financials performed over time
The total assets is 49% more than the total liabilities
Sarepta Therapeutics's quick ratio has decreased by 33% YoY and by 27% from the previous quarter
The total assets has decreased by 13% from the previous quarter but it has increased by 7% YoY
SRPT's debt is 18% greater than its equity
The debt to equity has increased by 36% since the previous quarter but it has declined by 18% year-on-year
The company's equity fell by 25% QoQ but it rose by 19% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.